These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30361677)

  • 61. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
    Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
    Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. LDL-cholesterol lowering and renal outcomes.
    Waters DD
    Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Chronic kidney disease and dyslipidaemia].
    Pascual V; Serrano A; Pedro-Botet J; Ascaso J; Barrios V; Millán J; Pintó X; Cases A
    Clin Investig Arterioscler; 2017; 29(1):22-35. PubMed ID: 27863896
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk.
    Werba JP; Vigo LM; Veglia F; Marenzi G; Tremoli E; Baldassarre D
    Clin Pharmacol Ther; 2019 Nov; 106(5):960-967. PubMed ID: 30916778
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Ezetimibe as a treatment for dyslipidaemia in CKD].
    Żebrowski P; Kaszyńska M
    Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 75. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.
    Wanner C; Tonelli M;
    Kidney Int; 2014 Jun; 85(6):1303-9. PubMed ID: 24552851
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
    Barter P; Ginsberg HN
    Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 78. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
    Calice-Silva V; Muenz D; Wong MMY; McCullough K; Charytan D; Reichel H; Robinson B; Stengel B; Massy ZA; Pecoits-Filho R;
    Lipids Health Dis; 2023 May; 22(1):67. PubMed ID: 37231413
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Dyslipidemia and the risk of kidney disease].
    Ligabue G; Cavazzini F; Albertazzi A
    G Ital Nefrol; 2007; 24 Suppl 38():8-12. PubMed ID: 17922441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.